...
search icon
prld-img

Prelude Therapeutics Inc Share Price

PRLD
NSQ
$2.38
+$0.11
(4.85%)
1D
Industry: Biotechnology Sector: Health Care

Prelude Therapeutics Inc Analyst Forecast

Prelude Therapeutics Inc Share Price Chart

Prelude Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$142.70M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
155.89K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.87
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.61 L
$4.22 H
$2.38

About Prelude Therapeutics Inc, Common Stock

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. more

Industry: BiotechnologySector: Health Care

Prelude Therapeutics Inc Stock Returns

Time FramePRLDSectorS&P500
1-Week Return1.34%0.81%0.49%
1-Month Return23.37%1.2%1.02%
3-Month Return35.93%3.24%3.34%
6-Month Return154.14%14.99%7.04%
1-Year Return152.22%7.42%11.68%
3-Year Return-59.46%20.71%71.63%
5-Year Return-97.05%37.45%75.56%
10-Year Return-91.34%138.53%257.55%

Prelude Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue----7.00M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue542.00K2.24M3.04M1.17M1.77M[{"date":"2020-12-31","value":17.82,"profit":true},{"date":"2021-12-31","value":73.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.43,"profit":true},{"date":"2024-12-31","value":58.25,"profit":true}]
Gross Profit(542.00K)(2.24M)(3.04M)(1.17M)7.00M[{"date":"2020-12-31","value":-7.74,"profit":false},{"date":"2021-12-31","value":-32.04,"profit":false},{"date":"2022-12-31","value":-43.46,"profit":false},{"date":"2023-12-31","value":-16.7,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin----100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses58.76M113.73M123.54M132.28M146.71M[{"date":"2020-12-31","value":40.05,"profit":true},{"date":"2021-12-31","value":77.52,"profit":true},{"date":"2022-12-31","value":84.2,"profit":true},{"date":"2023-12-31","value":90.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(58.76M)(113.73M)(123.54M)(132.28M)(139.71M)[{"date":"2020-12-31","value":-5876300000,"profit":false},{"date":"2021-12-31","value":-11373500000,"profit":false},{"date":"2022-12-31","value":-12354000000,"profit":false},{"date":"2023-12-31","value":-13227699900,"profit":false},{"date":"2024-12-31","value":-13971400000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(56.93M)(111.69M)(115.44M)(121.83M)(127.17M)[{"date":"2020-12-31","value":-5692900000,"profit":false},{"date":"2021-12-31","value":-11169400000,"profit":false},{"date":"2022-12-31","value":-11543800000,"profit":false},{"date":"2023-12-31","value":-12183200000,"profit":false},{"date":"2024-12-31","value":-12717300000,"profit":false}]
Income Taxes335.70K(915.00K)(8.10M)(1.00)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-272.56,"profit":false},{"date":"2022-12-31","value":-2413.44,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(56.93M)(111.69M)(115.44M)(117.40M)(127.17M)[{"date":"2020-12-31","value":-5692900000,"profit":false},{"date":"2021-12-31","value":-11169400000,"profit":false},{"date":"2022-12-31","value":-11543800000,"profit":false},{"date":"2023-12-31","value":-11739800000,"profit":false},{"date":"2024-12-31","value":-12717300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(56.93M)(110.78M)(107.34M)(121.83M)(127.17M)[{"date":"2020-12-31","value":-5692900000,"profit":false},{"date":"2021-12-31","value":-11077900000,"profit":false},{"date":"2022-12-31","value":-10733600000,"profit":false},{"date":"2023-12-31","value":-12183200000,"profit":false},{"date":"2024-12-31","value":-12717300000,"profit":false}]
EPS (Diluted)(11.20)(2.42)(2.44)(2.03)(1.68)[{"date":"2020-12-31","value":-1120,"profit":false},{"date":"2021-12-31","value":-242,"profit":false},{"date":"2022-12-31","value":-244,"profit":false},{"date":"2023-12-31","value":-203,"profit":false},{"date":"2024-12-31","value":-168,"profit":false}]

Prelude Therapeutics Inc Ratios

Prelude Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

PRLD
Cash Ratio 3.02
Current Ratio 3.21

Prelude Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PRLD
ROA (LTM) -51.82%
ROE (LTM) -103.99%

Prelude Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PRLD
Debt Ratio Lower is generally better. Negative is bad. 0.38
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.62

Prelude Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PRLD
Trailing PE NM
Forward PE NM
P/S (TTM) 13.59
P/B 2.41
Price/FCF NM
EV/R 9.88
EV/Ebitda NM

FAQs

What is Prelude Therapeutics Inc share price today?

Prelude Therapeutics Inc (PRLD) share price today is $2.38

Can Indians buy Prelude Therapeutics Inc shares?

Yes, Indians can buy shares of Prelude Therapeutics Inc (PRLD) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PRLD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Prelude Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Prelude Therapeutics Inc (PRLD) via the Vested app. You can start investing in Prelude Therapeutics Inc (PRLD) with a minimum investment of $1.

How to invest in Prelude Therapeutics Inc shares from India?

You can invest in shares of Prelude Therapeutics Inc (PRLD) via Vested in three simple steps:

  • Click on Sign Up or Invest in PRLD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Prelude Therapeutics Inc shares
What is Prelude Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Prelude Therapeutics Inc (PRLD) is $4.22. The 52-week low price of Prelude Therapeutics Inc (PRLD) is $0.61.

What is Prelude Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Prelude Therapeutics Inc (PRLD) is

What is Prelude Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Prelude Therapeutics Inc (PRLD) is 2.41

What is Prelude Therapeutics Inc dividend yield?

The dividend yield of Prelude Therapeutics Inc (PRLD) is 0.00%

What is the Market Cap of Prelude Therapeutics Inc?

The market capitalization of Prelude Therapeutics Inc (PRLD) is $142.70M

What is Prelude Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Prelude Therapeutics Inc is PRLD

How Can Investors Use Prelude Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Prelude Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Prelude Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Prelude Therapeutics Inc shares for Indian investors?

When investing in Prelude Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Prelude Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Prelude Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Prelude Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Prelude Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top